Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations

Collaborations:
Candid Therapeutics has entered into strategic research collaborations with EpimAb Biotherapeutics and Nona Biosciences to discover and develop novel T-cell engager (TCE) antibodies for autoimmune indications14.

Focus:
Candid Therapeutics is a clinical-stage biotechnology company focused on advancing T-cell engagers for autoimmune diseases, particularly targeting B-cell depletion14.

Partnerships:

EpimAb Biotherapeutics:
The collaboration aims to leverage EpimAb's expertise in multi-specific antibodies to broaden Candid's pipeline of TCEs for autoimmune diseases1.

Nona Biosciences:
The agreement includes a discovery collaboration and license agreement, with Nona Biosciences eligible to receive up to $320 million in upfront and milestone payments4.

Goals:
Candid Therapeutics aims to explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets and evaluating different depths of B-cell depletion14.

Background:
T-cell engagers are a promising therapeutic approach that requires careful optimization of both CD3-binding and tumor-targeting arms to ensure effective and safe treatment25.

Sources:

1. https://www.businesswire.com/news/home/20241216821817/en/Candid-Therapeutics-and-EpimAb-Biotherapeutics-Enter-Into-Research-Collaboration-to-Discover-and-Develop-Novel-T-Cell-Engagers-for-Autoimmune-Indications

2. https://jitc.bmj.com/content/10/Suppl_2/A1240

4. https://www.biospace.com/press-releases/nona-biosciences-announces-discovery-collaboration-with-candid-therapeutics-for-next-generation-t-cell-engagers

5. https://abcellera.com/post/sitc-2023-streamlining-t-cell-engager-development/